TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00620737

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Human Fibroblasts (Isolagen TherapyTM)
Description: 1. Collection of skin biopsy.~2. Administration of 2 study injections~3. Performance of various study assessments during clinic visits

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1. Collection of skin biopsy.~2. Administration of 2 study injections~3. Performance of various study assessments during clinic visits
Study: NCT00108277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing Training-Raise CO2
Description: while breathing 9 breaths per minute, patients are instructed to raise CO2
Study: NCT00108277

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breathing Training- Lower CO2
Description: while breathing 9 breaths per minute, patients are instructed to lower CO2
Study: NCT03217240

Intervention type: OTHER
Intervention: Blood Sampling for all participants
Description: Serum samples will be obtained before CMR. The sample will be stored at -80 degree until assay. Investigators will perform various tests related to participants heart function

Intervention type: OTHER
Intervention: Blood Sampling for all participants
Description: Serum samples will be obtained before CMR. The sample will be stored at -80 degree until assay. Investigators will perform various tests related to participants heart function
Study: NCT01310270

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pro-Omega
Description: Pro-Omega, 4.4gm/day x 1 month

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Omega 3 Fatty Acid
Description: 4.4 gm/day for 1 month

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega 3 Fatty Acid
Description: 4.4 gm/day for 1 month
Study: NCT04181723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trofinetide
Description: Trofinetide solution administered based on the subject's weight at Baseline, twice daily for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Trofinetide placebo solution administered based on the subject's weight at Baseline, twice daily for 12 weeks
Study: NCT04098289

Intervention type: PROCEDURE
Intervention: Hysteroscopic septum resection
Description: Hysteroscopic septum resection, using a 26 French continuous-flow resectoscope with monopolar energy and electrolyte-free distension medium.

Intervention type: PROCEDURE
Intervention: Hysteroscopic septum resection
Description: Hysteroscopic septum resection, using a 26 French continuous-flow resectoscope with monopolar energy and electrolyte-free distension medium.

Intervention type: PROCEDURE
Intervention: In vitro fertilization
Description: Fertilization of oocytes with the spermatozoa of the partner, after induction of ovulation and capacitation of the sperm, using fertilization in vitro and embryo transfer (FIVET) or intracytoplasmic sperm injection (ICSI).

Intervention type: PROCEDURE
Intervention: In vitro fertilization
Description: Fertilization of oocytes with the spermatozoa of the partner, after induction of ovulation and capacitation of the sperm, using fertilization in vitro and embryo transfer (FIVET) or intracytoplasmic sperm injection (ICSI).
Study: NCT00718835

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: incentive-based contingency management
Description: Direct comparison of Contingent versus Noncontingent incentives in promoting abstinence from smoking among opioid-treatment patients. The biochemical measures of breath carbon monoxide levels and urinary cotinine are used to confirm smoking status. Participants receive voucher-based incentives either contingent upon demonstrating abstinence from recent smoking (Contingent condition) or independent of smoking status (Noncontingent control condition).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: incentive-based contingency management
Description: Direct comparison of Contingent versus Noncontingent incentives in promoting abstinence from smoking among opioid-treatment patients. The biochemical measures of breath carbon monoxide levels and urinary cotinine are used to confirm smoking status. Participants receive voucher-based incentives either contingent upon demonstrating abstinence from recent smoking (Contingent condition) or independent of smoking status (Noncontingent control condition).
Study: NCT01502098

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative early passive motion
Description: Shoulder exercises starting on the first postoperative day

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Sling
Description: Sling for 4 weeks
Study: NCT00653744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study: NCT04184505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: 75mg/mq/day subcutaneously for 7 days every 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Chemotherapy
Description: 1. cycle (induction): i.v. 3+7 (Citarabine 200 mg/m2 iv continuous infusion (24 h) for 7 days, Daunorubicine 60 mg/mq iv day 1-3)~2. cycle (consolidation): i.v. 3+7 (Citarabine 200 mg/m2 iv continuous infusion (24 h) for 7 days, Daunorubicine 45 mg/mq iv day 1-3)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation
Description: Allogeneic stem cell transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic stem cell transplantation
Description: Allogeneic stem cell transplantation
Study: NCT00759187

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: Brush twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan/Fluoride
Description: Half mouth toothbrushing twice daily for 4 days
Study: NCT04682418

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: xvision Spine sytem
Description: pedicle screw placement will be performed using the XVS navigation system
Study: NCT03331575

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Arm1 (Hypofractionated radiotherapy)
Description: hypofractionated RT（PTV-G60.5Gy/22Fx, 2.75Gy/Fx; PTV-C 49.5Gy/22Fx, 2.25Gy/Fx）, with concurrent chemotherapy : Cisplatin(20 mg/m2 d1) Docetaxel (20 mg/m2 d1),weekly, 6 cycles )

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Arm1 (Hypofractionated radiotherapy)
Description: hypofractionated RT（PTV-G60.5Gy/22Fx, 2.75Gy/Fx; PTV-C 49.5Gy/22Fx, 2.25Gy/Fx）, with concurrent chemotherapy : Cisplatin(20 mg/m2 d1) Docetaxel (20 mg/m2 d1),weekly, 6 cycles )
Study: NCT00759187

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine Gluconate
Description: Mouth rinsing twice a day for 4 days
Study: NCT04305587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07081532
Description: Investigational Drug once daily for up to 42 days; multiple ascending dose design.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-07081532
Description: Investigational Drug once daily for up to 42 days; multiple ascending dose design.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo once daily for up to 42 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for up to 42 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Part B may include a drug-drug interaction study using open-label clopidogrel. Clopidrogrel may be given as two single doses of 75 mg administered on day -2 and day 41.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Description: Part B may include a drug-drug interaction study using open-label clopidogrel. Clopidrogrel may be given as two single doses of 75 mg administered on day -2 and day 41.
Study: NCT01723618

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRD007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRD007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRD007
Study: NCT03812744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Whole coffee cherry extract (WCCE)
Description: 100mg WCCE

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule [CEBOCAP]
Description: Silica Oxide
Study: NCT00927797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Pentostatin, Rituximab
Study: NCT04096755

Intervention type: DIAGNOSTIC_TEST
Intervention: Procedure
Description: serum and urine samples will be taken for analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Procedure
Description: serum and urine samples will be taken for analysis
Study: NCT02581722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrePex Device
Description: The PrePex device is designed to enable conducting male circumcision procedure that is bloodless with no anesthesia and no sutures. For contraindicated subjects, a preparation procedure will take place.
Study: NCT00650208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine Tablets 25 mg
Description: 2x25mg, single dose fasting
Study: NCT00653744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Study: NCT04036344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Mentorship Program
Description: Mentee participants are paired with a previous MMS patient (Mentor) who is greater than 1 year status post MMS treatment for a facial skin cancer. Mentors and mentees maintain regular contact by telephone, video chat, or in-person meetings throughout the mentee's facial skin cancer treatment with MMS.
Study: NCT00650208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamictal® Tablets 25 mg
Description: 2x25mg, single dose fasting
Study: NCT04249674

Intervention type: DIAGNOSTIC_TEST
Intervention: Dextrometorphan
Description: Administration of 4 ml=10 mg of Dextrometorphan (Bexine sirup)

Intervention type: DIAGNOSTIC_TEST
Intervention: Dextrometorphan
Description: Administration of 4 ml=10 mg of Dextrometorphan (Bexine sirup)

Intervention type: GENETIC
Intervention: Genotyping by single nulcetoide polymorphism.
Description: Single nucleotide polymorphism determination

Intervention type: GENETIC
Intervention: Genotyping by single nulcetoide polymorphism.
Description: Single nucleotide polymorphism determination
Study: NCT03104959

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Study: NCT03206463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg Delta-9-THC
Description: Subject will have 1/3 chance of receiving 4 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
Study: NCT03104959

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01507623

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capnography (Phillips MP20 monitor)
Description: In the intervention group the NAPS nurse observed possible hypoxia and changes in capnography curves/values during the procedure and was instructed to decrease propofol and take actions against insufficient ventilation\* if etCO2 ≥ 7kPa or ≤ 2 kPa for ≥ 1 minute, if respiratory frequency ≤ 8 or a loss of curve shape was registered.~\*Suction, increase oxygen supply, tongue holder or nasal airway, bag-mask ventilation,paged anaesthesia Discontinued procedures
Study: NCT03512275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bermekimab Monoclonal Antibody 400 mg
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bermekimab Monoclonal Antibody 400 mg
Description: subcutaneous injection
Study: NCT02280525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 2.5 mg by mouth daily on Day -2 to Day +14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 2.5 mg by mouth daily on Day -2 to Day +14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 2.5 mg by mouth daily on Day -2 to Day +14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 by vein on Day -5 for participants with B-cell cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting Chemotherapy Option #1: Fludarabine 25 mg/m2 by vein on Days -5 to -3.~Lymphodepleting Chemotherapy Option #2: Fludarabine 25 mg/m2 by vein over 1 hour on Day -6 to -2.~Lymphodepleting Chemotherapy Option #3: Fludarabine 30 mg/m2 by vein over 1 hour on Days -6 to -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting Chemotherapy Option #1: Fludarabine 25 mg/m2 by vein on Days -5 to -3.~Lymphodepleting Chemotherapy Option #2: Fludarabine 25 mg/m2 by vein over 1 hour on Day -6 to -2.~Lymphodepleting Chemotherapy Option #3: Fludarabine 30 mg/m2 by vein over 1 hour on Days -6 to -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting Chemotherapy Option #1: Fludarabine 25 mg/m2 by vein on Days -5 to -3.~Lymphodepleting Chemotherapy Option #2: Fludarabine 25 mg/m2 by vein over 1 hour on Day -6 to -2.~Lymphodepleting Chemotherapy Option #3: Fludarabine 30 mg/m2 by vein over 1 hour on Days -6 to -2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting Chemotherapy Option #1: Cyclophosphamide 200 mg/m2 by vein on Days -5 to -3.~Lymphodepleting Chemotherapy Option #2: Cyclophosphamide 60 mg/kg by vein over 3 hours on Days -5 and -4.
Study: NCT03206463

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject will have 1/3 chance of receiving the inhaled placebo condition administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing. The placebo condition will include no active cannabinoids.
Study: NCT01738321

Intervention type: OTHER
Intervention: Cuff pressure
Description: Measuring endotracheal tube (ETT) cuff pressure
Study: NCT02280525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting Chemotherapy Option #1: Cyclophosphamide 200 mg/m2 by vein on Days -5 to -3.~Lymphodepleting Chemotherapy Option #2: Cyclophosphamide 60 mg/kg by vein over 3 hours on Days -5 and -4.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NK Cells
Description: Participant assigned to a dose level of NK cells based on when joined study. Starting dose level of NK cells 1 x 10\^7 NK cells/kg given by vein on Day 0.~NK Cell Infusion Expansion Phase: Maximum tolerated dose of NK cells from Induction Phase.
Study: NCT03206463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg Delta-9-THC
Description: Subject will have 1/3 chance of receiving 2 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
Study: NCT01381666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INS316 solution for inhalation
Description: inhalation via nebulizer given for 2 doses for 60 minutes each

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hypertonic saline 3% sodium chloride solution
Description: inhalation via nebulizer given for 2 doses for 60 minutes each
Study: NCT02280525

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NK Cells
Description: Participant assigned to a dose level of NK cells based on when joined study. Starting dose level of NK cells 1 x 10\^7 NK cells/kg given by vein on Day 0.~NK Cell Infusion Expansion Phase: Maximum tolerated dose of NK cells from Induction Phase.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NK Cells
Description: Participant assigned to a dose level of NK cells based on when joined study. Starting dose level of NK cells 1 x 10\^7 NK cells/kg given by vein on Day 0.~NK Cell Infusion Expansion Phase: Maximum tolerated dose of NK cells from Induction Phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine 2 mg/m2 by vein on Days -6 to -2.
Study: NCT04370405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY-20394
Description: YY-20394 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
Study: NCT03729089

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Biophysical Profile scan
Description: Modified biophysical profile scan to be done in third trimester for eligible pregnant mothers
Study: NCT01161927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nizatidine
Description: Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Axid
Description: Axid 300 mg Capsules of Reliant Pharmaceuticals, US
Study: NCT04125849

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoraco-laparoscopic esophagectomy
Description: Thoraco-laparoscopic esophagectomy surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mediastinoscopy-assisted transhiatal esophagectomy
Description: Mediastinoscopy-assisted transhiatal esophagectomy surgery
Study: NCT03214796

Intervention type: DRUG
Intervention: Human albumin
Description: Infusion of human albumin
Study: NCT03547076

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Focused ultrasound diagnostics
Description: Patients first be examined by nurses using a pocket-sized imaging device. Secondly, by a General Practitioner using the pocket-sized imaging device. Thirdly, reference echocardiography will be performed by cardiologist using a high-end echocardiographic scanner. Only tools (ultrasound equipment and dedicated software) approved for clinical practice will be used.~The focused ultrasound examination includes three standard apical views (4-chamber, 2-chamber and long axis) with and without color Doppler, in addition to recordings from both pleural cavities and the inferior vena cava. The reference imaging includes the same recordings, but in addition all other chambers and valves are assessed (grey scale, color Doppler, pulsed wave and continuous wave Doppler and tissue Doppler).
Study: NCT00509366

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin & Gemcitabine
Description: Squamous Cell NSCLC:~Gemcitabine 1250 mg/m2 IV over 30 minutes day 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin & Gemcitabine
Description: Squamous Cell NSCLC:~Gemcitabine 1250 mg/m2 IV over 30 minutes day 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin & Pemetrexed
Description: Non-Squamous Cell NSCLC:~Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel & Gemcitabine
Description: Squamous Cell NSCLC:~Docetaxel 75 mg/m2 IV over 60 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles
Study: NCT01310348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: whole-body vibration (WBV)
Description: The whole-body vibration (WBV) training group will be trained on a WBV platform (Power Plate) 5 times a week for 4 weeks period. Training volume and training intensity will be low at the beginning but progressed slowly according to the overload principle. The training volume will be increased systematically over the 4-week training period. The training intensity will be increased by increasing the amplitude (2-4 mm) and the frequency (40 Hz) of the vibration.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: WBV (Sham stimulation)
Description: Sham stimulus will be performed by WBV platform 5 times a week for a 4 weeks period.
Study: NCT00439413

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selegiline Transdermal Patch
Description: Selegiline cm(2) via transdermal system

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo via transdermal system

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Smoking Cessation Counseling
Description: Subjects were provided with on-site, individual smoking cessation counseling sessions 1x per week for 9 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation Counseling
Description: Subjects were provided with on-site, individual smoking cessation counseling sessions 1x per week for 9 weeks
Study: NCT03614273

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline
Description: The nebulizations were administered via an oxygen run jet nebulizer, with a flow of 6-7 litres/min.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenaline
Description: The nebulizations were administered via an oxygen run jet nebulizer, with a flow of 6-7 litres/min.
Study: NCT04930406

Intervention type: OTHER
Intervention: Physical therapy
Description: Had to receive 10 or more visits of physical therapy during the cancer treatment period to qualify for intervention group.
Study: NCT01631851

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) for Irritability
Description: CBT is an individually administered behavioral interventions aimed at reducing irritability and disruptive behavior. There are 10 to 12 weekly sessions that are conducted with the child and the parent. During these sessions children are taught to recognize antecedents and consequences of problem behavior and to use emotion regulation and problem-solving skills to reduce irritability, aggression and noncompliance.
Study: NCT00439270

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: Tablets, Oral, 50, 70, 100, or 120 mg once daily; treatment may continue until disease progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: Tablets, Oral, 50, 70, 100, or 120 mg once daily; treatment may continue until disease progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: Tablets, Oral, 50, 70, 100, or 120 mg once daily; treatment may continue until disease progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: Tablets, Oral, 50, 70, 100, or 120 mg once daily; treatment may continue until disease progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dasatinib
Description: Tablets, Oral, 50, 70, 100, or 120 mg once daily; treatment may continue until disease progression

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Infusion, 60 or 75 mg/m\^2, administered every 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Infusion, 60 or 75 mg/m\^2, administered every 3 weeks.